Medicare Enrolled
Dr. Benjamin Kitchens, MD
Medical Oncology · Dallas, TX
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Kitchens from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Kitchens?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Kitchens
Dr. Benjamin Kitchens is a medical oncology specialist in Dallas, TX, with 13 years of NPI registration. Based on federal Medicare data, Dr. Kitchens performed 18,497 Medicare services in 2023. These records do not provide a deduplicated patient total.
Between the years covered by Open Payments, Dr. Kitchens received a total of $93,373 from 58 pharmaceutical and/or device companies across 363 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Kitchens is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 13 years of NPI registration
▲ Top 35% volume in TX
$93,373 industry payments
Medicare Practice Summary — 2023
Medicare Utilization ↗18,497
Medicare services
Top 35% in TX for medical oncology
Not available
Unique patients (not deduplicated)
$20
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Pembrolizumab injection (Keytruda) | 6,000 | $43 | $136 |
| Anti-nausea injection (fosaprepitant) An injection of fosaprepitant, a medication used to prevent nausea and vomiting. |
4,200 | $0 | $5 |
| Contrast dye for imaging (iodine-based) A contrast agent containing 300-399 mg/ml of iodine used to enhance imaging studies. It is administered per milliliter to improve the visibility of internal structures. |
2,509 | $0 | $3 |
| Paclitaxel chemotherapy injection | 1,784 | $0 | $8 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
775 | $0 | $1 |
| Injection, granisetron hydrochloride, 100 mcg | 370 | $0 | $24 |
| Anti-nausea injection (Aloxi/palonosetron) | 370 | $1 | $114 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
368 | $93 | $368 |
| Comprehensive metabolic blood panel A blood test that measures a group of chemicals, including glucose, electrolytes, and kidney and liver function markers. |
350 | $10 | $64 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
306 | $8 | $36 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
277 | $8 | $20 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
129 | $22 | $157 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
112 | $103 | $707 |
| Carcinoembryonic antigen (CEA) level test A blood test that measures the level of carcinoembryonic antigen (CEA) protein. This test is used to monitor certain types of cancer. |
93 | $18 | $99 |
| Fluorouracil injection, 500 mg Administration of a 500 mg dose of fluorouracil medication via injection. |
91 | $2 | $13 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
90 | $12 | $108 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
80 | $93 | $357 |
| Carboplatin chemotherapy injection, 50 mg Administration of a 50 mg dose of carboplatin, a chemotherapy medication, via injection. |
80 | $2 | $300 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
68 | $7 | $431 |
| Manual white blood cell count A laboratory test that involves examining a sample under a microscope to manually count the number of white blood cells present. |
44 | $4 | $22 |
| Complete blood count (CBC), automated An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood. |
44 | $6 | $34 |
| New patient office visit, complex (60-74 min) | 37 | $166 | $709 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
30 | $48 | $313 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
30 | $127 | $496 |
| Magnesium level test A blood test to measure the amount of magnesium in your body. This helps check for magnesium deficiency or excess. |
27 | $7 | $29 |
| CT scan of chest with contrast A computed tomography scan of the chest using a contrast dye to enhance the visibility of internal structures. |
25 | $51 | $821 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
24 | $52 | $344 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
23 | $1 | $7 |
| CT scan of abdomen and pelvis with contrast A CT scan that uses dye to create detailed images of the abdomen and pelvis. This imaging test helps doctors examine internal organs and structures in these areas. |
20 | $163 | $1,067 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
19 | $1 | $8 |
| Irrigation of implanted venous access device This procedure involves flushing an implanted venous access device to clear blockages or maintain patency. It ensures the device remains functional for delivering medications or fluids. |
15 | $19 | $114 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
15 | $136 | $694 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
15 | $2 | $19 |
| Nuclear medicine scan from skull base to mid-thigh with CT A nuclear medicine imaging study covering the area from the base of the skull to the middle of the thighs, performed alongside a CT scan. |
14 | $1,182 | $4,802 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
14 | $11 | $96 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
13 | $54 | $211 |
| Concurrent intravenous infusion Administration of medication or fluid into a vein for therapy, prevention, or diagnosis while another infusion is being given. |
12 | $14 | $94 |
| Intravenous chemotherapy injection Chemotherapy medication is administered directly into a vein using a push technique. This method involves injecting the drug through a needle or catheter already placed in the vein. |
12 | $81 | $500 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 12 | $90 | $657 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. These counts do not measure clinical quality or years of experience.
1.7% high complexity
89.0% medium
9.3% routine
Industry Payment Transparency
Open Payments through 2024 ↗$93,373
Total received (2018-2024)
Avg $13,339/year across 7 years
Top 15% in TX for medical oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
58
Companies
363
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →
Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$63,930
2023
$25,208
2022
$800
2021
$853
2020
$1,100
2019
$881
2018
$601
Payments by company (2024)
Ipsen Biopharmaceuticals, Inc
$16,588
Astellas Pharma US Inc
$15,078
Takeda Pharmaceuticals U.S.A., Inc.
$13,870
AstraZeneca Pharmaceuticals LP
$9,818
JAZZ PHARMACEUTICALS INC.
$6,020
Genentech USA, Inc.
$1,307
ABBVIE INC.
$201
Merck Sharp & Dohme LLC
$195
Eisai Inc.
$139
Incyte Corporation
$137
SERVIER PHARMACEUTICALS LLC
$128
PFIZER INC.
$84
Iovance Biotherapeutics, Inc.
$61
Aveo Pharmaceuticals, Inc.
$57
Regeneron Healthcare Solutions, Inc.
$47
SOBI, INC
$33
Dendreon Pharmaceuticals LLC
$33
Janssen Biotech, Inc.
$31
Blueprint Medicines Corporation
$28
ARRAY BIOPHARMA INC
$26
E.R. Squibb & Sons, L.L.C.
$20
Genmab U.S., Inc.
$15
Rigel Pharmaceuticals, Inc.
$15
Top 3 companies account for 71.2% of 2024 payments
All-time payments by company (2018-2024) ›
Astellas Pharma US Inc
$31,301
Ipsen Biopharmaceuticals, Inc
$18,373
AstraZeneca Pharmaceuticals LP
$16,376
Takeda Pharmaceuticals U.S.A., Inc.
$13,882
JAZZ PHARMACEUTICALS INC.
$6,020
Genentech USA, Inc.
$1,434
Incyte Corporation
$710
Janssen Biotech, Inc.
$507
ABBVIE INC.
$453
Merck Sharp & Dohme LLC
$297
PFIZER INC.
$275
Eisai Inc.
$242
Regeneron Healthcare Solutions, Inc.
$222
Seagen Inc.
$215
E.R. Squibb & Sons, L.L.C.
$210
Adaptive Biotechnologies Corporation
$206
Merck Sharp & Dohme Corporation
$183
Novartis Pharmaceuticals Corporation
$173
GlaxoSmithKline, LLC.
$146
Boston Scientific Corporation
$145
SERVIER PHARMACEUTICALS LLC
$128
Amgen Inc.
$116
Pharmacosmos Therapeutics Inc.
$115
CSL Behring
$112
Rigel Pharmaceuticals, Inc.
$111
GENZYME CORPORATION
$110
Blueprint Medicines Corporation
$89
Clovis Oncology, Inc.
$76
Bayer Healthcare Pharmaceuticals Inc.
$75
Dova Pharmaceuticals
$63
Karyopharm Therapeutics Inc.
$61
Iovance Biotherapeutics, Inc.
$61
Foundation Medicine, Inc.
$61
Boehringer Ingelheim Pharmaceuticals, Inc.
$59
Aveo Pharmaceuticals, Inc.
$57
SOBI, INC
$57
Janssen Pharmaceuticals, Inc
$50
Kite Pharma, Inc.
$47
ARRAY BIOPHARMA INC
$44
Epizyme, Inc.,
$44
Allergan Inc.
$44
ADC Therapeutics America, Inc.
$38
Acrotech Biopharma LLC
$35
Dendreon Pharmaceuticals LLC
$33
Genmab U.S., Inc.
$33
Deciphera Pharmaceuticals Inc.
$30
Pharmacyclics LLC, An AbbVie Company
$26
Taiho Oncology, Inc.
$26
Jazz Pharmaceuticals Inc.
$24
Cumberland Pharmaceuticals, Inc.
$24
Sun Pharmaceutical Industries Inc.
$23
AVEO Pharmaceuticals, Inc.
$23
PORTOLA PHARMACEUTICALS, INC.
$22
Sobi, Inc
$21
Acrotech Biopharma Inc.
$17
Mylan Specialty L.P.
$17
MorphoSys, US Inc.
$15
Novo Nordisk Inc
$15
Top 3 companies account for 70.7% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · AYVAKIT · Alecensa · Amtagvi · BELEODAQ · BEVYXXA · BLENREP · BRAFTOVI · Blincyto · CALQUENCE · CARVYKTI · CHANTIX · CREON · CRESEMBA · Caldolor · DARZALEX · DIFICID · Doptelet · ELIQUIS · ELITEK · ENTRESTO · EPKINLY · EVENITY · Epkinly · FOTIVDA · FRUZAQLA · GAMIFANT · Gamifant · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · IMJUDO · INLYTA · JAKAFI · JARDIANCE · KEYTRUDA · Kcentra · Kyprolis · LIBTAYO · LOKELMA · LONSURF · LYNPARZA · Lenvima · Lonsurf · MONJUVI · MONOFERRIC · MVASI · MYCAMINE · Nubeqa · OPDIVO · Odomzo · Onivyde · PADCEV · PEMAZYRE · PRADAXA · PROVENGE · Padcev · QINLOCK · Rezlidhia · Rubraca · SCEMBLIX · TAGRISSO · TASIGNA · TAZVERIK · TECENTRIQ · TEFLARO · TUKYSA · Tavalisse · TheraSphere Y90 Glass Microspheres 10 GBq · Tibsovo · VENCLEXTA · VONJO · Vyloy · XALKORI · XARELTO · XPOVIO · XTANDI · Xtandi · Yupelri · ZEPZELCA · ZERBAXA · ZIIHERA · clonoSEQ
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Geographic Context
Medical oncologists in nearby ZIP areas
90
County median income
$74,149
Nearest hospital to ZIP centroid (approximate)
BAYLOR UNIVERSITY MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | NPPES snapshot; verify current record |
| Medicare Enrollment | ✓ PECOS | PECOS snapshot |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not included | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Kitchens is a mixed practice specialist, with moderate Medicare volume.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Kitchens experienced with pembrolizumab injection (keytruda)?
Based on Medicare claims data, Dr. Kitchens performed 6,000 pembrolizumab injection (keytruda) services. These records cover Medicare fee-for-service activity, including eligible younger beneficiaries; they do not measure total practice volume or clinical quality.
Does Dr. Kitchens receive payments from pharmaceutical companies?
Yes. Dr. Kitchens received a total of $93,373 from 58 companies across 363 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Kitchens's costs compare to other medical oncologists in Dallas?
Dr. Kitchens's average Medicare payment per service is $20. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Kitchens) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologists in Dallas
Browse medical oncologists in Dallas ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologists in TX
Medical oncologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologists in TX
Which TX medical oncologists receive the most from drug and device companies.
By company
Astellas Pharma US Inc Payments to Doctors
See all physicians who received payments from Astellas Pharma US Inc.
By company
Ipsen Biopharmaceuticals, Inc Payments to Doctors
See all physicians who received payments from Ipsen Biopharmaceuticals, Inc.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
About this page
This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology